secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009911
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge positive Phase 1 data for BGE-102: 86% hsCRP reduction, 93% normalized
-----------------------------------------------------------------------------

- BGE-102 achieved 86% median hsCRP reduction at Day 14 in obese patients with elevated baseline hsCRP; 93% reached <2 mg/L.
- Significant reductions in IL-6 (44%) and fibrinogen (30%) observed, indicating downstream inflammatory cascade suppression.
- BGE-102 well tolerated with no dose-limiting toxicities; favorable safety profile.
- Phase 1 completion and Phase 2a initiation in obese patients with CV risk factors expected in 1H 2026.
- Patent issued covering additional composition of matter and novel NLRP3 binding site.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526009911/0001193125-26-009911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526009911/bioa-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer